South Korea · Delayed Price · Currency is KRW Medy-Tox Statistics
Total Valuation
Medy-Tox has a market cap or net worth of KRW 439.81 billion. The enterprise value is 521.36 billion.
| Market Cap | 439.81B |
| Enterprise Value | 521.36B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
Medy-Tox has 6.46 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 6.46M |
| Shares Outstanding | 6.46M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -1.07% |
| Owned by Insiders (%) | 21.22% |
| Owned by Institutions (%) | 9.93% |
| Float | 5.02M |
Valuation Ratios
The trailing PE ratio is 30.43 and the forward PE ratio is 15.63.
| PE Ratio | 30.43 |
| Forward PE | 15.63 |
| PS Ratio | 1.75 |
| PB Ratio | 1.16 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | 8.09 |
| P/OCF Ratio | 6.43 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.29, with an EV/FCF ratio of 9.58.
| EV / Earnings | 36.35 |
| EV / Sales | 2.08 |
| EV / EBITDA | 17.29 |
| EV / EBIT | 51.93 |
| EV / FCF | 9.58 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.03 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 3.36 |
| Debt / FCF | 2.29 |
| Interest Coverage | 26.21 |
Financial Efficiency
Return on equity (ROE) is 3.59% and return on invested capital (ROIC) is 3.71%.
| Return on Equity (ROE) | 3.59% |
| Return on Assets (ROA) | 1.84% |
| Return on Invested Capital (ROIC) | 3.71% |
| Return on Capital Employed (ROCE) | 4.06% |
| Weighted Average Cost of Capital (WACC) | 5.18% |
| Revenue Per Employee | 357.15M |
| Profits Per Employee | 20.40M |
| Employee Count | 703 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.17 |
Taxes
| Income Tax | -7.39B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.19% in the last 52 weeks. The beta is 0.41, so Medy-Tox's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -47.19% |
| 50-Day Moving Average | 71,170.00 |
| 200-Day Moving Average | 99,486.00 |
| Relative Strength Index (RSI) | 42.09 |
| Average Volume (20 Days) | 30,766 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medy-Tox had revenue of KRW 251.08 billion and earned 14.34 billion in profits. Earnings per share was 2,237.82.
| Revenue | 251.08B |
| Gross Profit | 154.99B |
| Operating Income | 17.02B |
| Pretax Income | 7.76B |
| Net Income | 14.34B |
| EBITDA | 37.14B |
| EBIT | 17.02B |
| Earnings Per Share (EPS) | 2,237.82 |
Balance Sheet
The company has 47.98 billion in cash and 124.63 billion in debt, with a net cash position of -76.65 billion or -11,868.93 per share.
| Cash & Cash Equivalents | 47.98B |
| Total Debt | 124.63B |
| Net Cash | -76.65B |
| Net Cash Per Share | -11,868.93 |
| Equity (Book Value) | 379.35B |
| Book Value Per Share | 57,979.47 |
| Working Capital | 5.24B |
Cash Flow
In the last 12 months, operating cash flow was 68.38 billion and capital expenditures -13.98 billion, giving a free cash flow of 54.40 billion.
| Operating Cash Flow | 68.38B |
| Capital Expenditures | -13.98B |
| Depreciation & Amortization | 20.12B |
| Net Borrowing | 47.09B |
| Free Cash Flow | 54.40B |
| FCF Per Share | 8,422.60 |
Margins
Gross margin is 61.73%, with operating and profit margins of 6.78% and 6.10%.
| Gross Margin | 61.73% |
| Operating Margin | 6.78% |
| Pretax Margin | 3.09% |
| Profit Margin | 6.10% |
| EBITDA Margin | 14.79% |
| EBIT Margin | 6.78% |
| FCF Margin | 21.66% |
Dividends & Yields
This stock pays an annual dividend of 1,200.00, which amounts to a dividend yield of 1.78%.
| Dividend Per Share | 1,200.00 |
| Dividend Yield | 1.78% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 58.22% |
| FCF Payout Ratio | 14.25% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 1.80% |
| Earnings Yield | 3.26% |
| FCF Yield | 12.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Medy-Tox is 92,000.00, which is 36.70% higher than the current price. The consensus rating is "Hold".
| Price Target | 92,000.00 |
| Price Target Difference | 36.70% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.94% |
| EPS Growth Forecast (3Y) | 42.41% |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Medy-Tox has an Altman Z-Score of 4.02 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.02 |
| Piotroski F-Score | 6 |